Published in Retrovirology on February 03, 2011
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One (2011) 0.92
Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues. PLoS One (2014) 0.82
Upregulation of TRIM5α gene expression after live-attenuated simian immunodeficiency virus vaccination in Mauritian cynomolgus macaques, but TRIM5α genotype has no impact on virus acquisition or vaccination outcome. J Gen Virol (2012) 0.81
Expression of the memory marker CD45RO on helper T cells in macaques. PLoS One (2013) 0.76
Live attenuated simian immunodeficiency virus vaccination confers superinfection resistance against macrophage-tropic and neurovirulent wild-type SIV challenge. J Gen Virol (2015) 0.76
Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic antiretroviral therapy. AIDS (2016) 0.76
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 11.12
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest (1998) 6.51
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 6.30
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med (2004) 3.62
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet (1995) 3.47
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med (1999) 3.30
Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 3.13
CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A (1999) 3.07
Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS (2000) 2.99
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
The anatomical basis of intestinal immunity. Immunol Rev (1997) 2.57
Do most lymphocytes in humans really reside in the gut? Trends Immunol (2007) 2.49
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol (1998) 2.49
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 2.41
Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood (2006) 2.40
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol (2000) 2.37
Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med (2000) 2.10
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation. Eur J Immunol (2000) 1.80
Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol (1994) 1.77
Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum Retroviruses (1998) 1.73
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol (1997) 1.62
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol (1995) 1.56
Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med (2006) 1.55
Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J Exp Med (2009) 1.51
Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS (2003) 1.50
Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology (1998) 1.47
Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis (2000) 1.38
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci U S A (2004) 1.30
Gut intraepithelial T lymphocytes. Curr Opin Immunol (1993) 1.30
Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J Virol (2000) 1.29
Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS (1998) 1.27
Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression. AIDS (2007) 1.23
Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc Natl Acad Sci U S A (1989) 1.21
Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol (2005) 1.18
Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol (1998) 1.18
Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol (2008) 1.11
Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes. J Immunol (2002) 1.10
Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine. Virology (2000) 1.08
The gastrointestinal tract and the pathogenesis of AIDS. AIDS (1998) 1.08
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol (2005) 1.05
Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology (2004) 1.04
Accumulation of CCR5+ T cells around RANTES+ granulomas in Crohn's disease: a pivotal site of Th1-shifted immune response? Lab Invest (2005) 1.04
Mechanisms of protection induced by attenuated simian immunodeficiency virus. Virology (2002) 1.03
Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope. J Gen Virol (2004) 1.01
CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques. J Virol (2007) 1.00
Mechanisms of protection against simian immunodeficiency virus infection. Vaccine (2002) 0.98
Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. Virology (2003) 0.95
Vaccination with SIVmac239Deltanef activates CD4+ T cells in the absence of CD4 T-cell loss. J Med Primatol (2009) 0.94
Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology (2010) 0.91
Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr Opin HIV AIDS (2008) 0.91
Highly attenuated SIVmac142 is immunogenic but does not protect against SIVmac251 challenge. AIDS Res Hum Retroviruses (1995) 0.90
Attenuated SIV imparts immunity to challenge with pathogenic spleen-derived SIV but cannot prevent repair of the nef deletion. Immunol Lett (1996) 0.85
Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. Med Sci Monit (2006) 0.80
Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo. J Med Primatol (2007) 0.78
Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection. Virology (2008) 0.78
Immunological responses and viral modulatory effects of vaccination with recombinant modified vaccinia virus Ankara (rMVA) expressing structural and regulatory transgenes of simian immunodeficiency virus (SIVmac32H/J5M). J Med Primatol (2007) 0.76
High-throughput mapping of a dynamic signaling network in mammalian cells. Science (2005) 5.21
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
The African coelacanth genome provides insights into tetrapod evolution. Nature (2013) 2.78
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther (2008) 1.81
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg (2011) 1.80
Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg (2003) 1.50
Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol (2012) 1.45
A method for internal fixation of unstable distal clavicle fractures: early observations using a new technique. J Shoulder Elbow Surg (2007) 1.28
The transition to social inbred mating systems in spiders: role of inbreeding tolerance in a subsocial predecessor. Evolution (2005) 1.28
Accuracy of thoracic pedicle screws in patients with and without coronal plane spinal deformities. Spine (Phila Pa 1976) (2002) 1.25
Adaptation of the genetically tractable malaria pathogen Plasmodium knowlesi to continuous culture in human erythrocytes. Proc Natl Acad Sci U S A (2012) 1.24
Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol Pharmacol (2008) 1.22
Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics (2009) 1.14
MHC haplotype frequencies in a UK breeding colony of Mauritian cynomolgus macaques mirror those found in a distinct population from the same geographic origin. J Med Primatol (2008) 1.13
Investigation of porcine circovirus contamination in human vaccines. Biologicals (2012) 1.12
Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol (2008) 1.11
Complete Genome Sequence of the WHO International Standard for HIV-1 RNA Determined by Deep Sequencing. Genome Announc (2014) 1.09
How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine (2013) 1.08
Biogeography and speciation patterns of the golden orb spider genus Nephila (Araneae: Nephilidae) in Asia. Zoolog Sci (2011) 1.08
Human CD4+ lymphocytes for antigen quantification: characterization using conventional flow cytometry and mass cytometry. Cytometry A (2012) 1.07
Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS (2003) 1.07
Myxobacteria, polarity, and multicellular morphogenesis. Cold Spring Harb Perspect Biol (2010) 1.07
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol (2005) 1.05
Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology (2004) 1.04
Mechanisms of protection induced by attenuated simian immunodeficiency virus. Virology (2002) 1.03
Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol (2006) 1.02
Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope. J Gen Virol (2004) 1.01
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem (2009) 1.01
Caveolin-1 knockout mice have increased bone size and stiffness. J Bone Miner Res (2007) 1.01
Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology (2010) 1.00
The focal adhesion kinase amino-terminal domain localises to nuclei and intercellular junctions in HEK 293 and MDCK cells independently of tyrosine 397 and the carboxy-terminal domain. Biochem Biophys Res Commun (2002) 1.00
Preparation and evaluation of the 1st international standard for the quantitation of HIV-2 RNA in plasma. J Virol Methods (2011) 1.00
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines. J Med Chem (2004) 0.98
Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol (2010) 0.98
Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity. J Med Chem (2010) 0.98
Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol (2003) 0.97
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol (2013) 0.96
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods (2009) 0.95
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol (2011) 0.93
The meninges is a source of retinoic acid for the late-developing hindbrain. J Neurosci (2003) 0.93
Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. Retrovirology (2008) 0.92
Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging (2010) 0.92
Effect of an iPod video intervention on consent to donate organs: a randomized trial. Ann Intern Med (2012) 0.92
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One (2011) 0.92
Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine (2008) 0.92
Quantification of Human T-lymphotropic virus type I (HTLV-I) provirus load in a rural West African population: no enhancement of human immunodeficiency virus type 2 pathogenesis, but HTLV-I provirus load relates to mortality. J Infect Dis (2003) 0.90
Managing pain: The Challenge in Underserved Populations: Appropriate Use Versus Abuse and Diversion. J Natl Med Assoc (2004) 0.89
Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant (2003) 0.89
International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma. J Clin Microbiol (2010) 0.88
Chronic fatigue syndrome: xenotropic murine leukemia virus-related virus, murine leukemia virus, both, or neither? Proc Natl Acad Sci U S A (2010) 0.88
High-precision radiocarbon dating and historical biblical archaeology in southern Jordan. Proc Natl Acad Sci U S A (2008) 0.88
Ethanol increases retinoic acid production in cerebellar astrocytes and in cerebellum. Brain Res Dev Brain Res (2004) 0.88
Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther (2011) 0.86
Safety pharmacology--current and emerging concepts. Toxicol Appl Pharmacol (2013) 0.86
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One (2012) 0.86
Ileitis secondary to oral capecitabine treatment? Case Rep Med (2012) 0.86
Identification, expression analysis, genomic organization and cellular location of a novel protein with a RhoGEF domain. Gene (2005) 0.86
How do we assure the quality of biological medicines? Drug Discov Today (2008) 0.86
Critical care nurses provide their perspectives of patients' symptoms in intensive care units. Heart Lung (2008) 0.86
Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res Hum Retroviruses (2005) 0.86
Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol (2003) 0.85
Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine (2011) 0.85
The influence of Cardan rotation sequence on angular orientation data for the lower limb in the soccer kick. J Sports Sci (2010) 0.85
Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer. Surg Endosc (2010) 0.85